Perlegen Sciences

About:

Perlegen Sciences develops genetic variations providing physicians with information to improve the clinical process and treatment outcomes.

Website: http://www.perlegen.com/

Top Investors: Eli Lilly, Unilever Ventures, Maverick Ventures, Mizuho Securities, Glynn Capital Management

Description:

Perlegen Sciences engages in the discovery and commercialization of genetic variations that provide physicians with information to improve the clinical decision-making process and patient treatment outcomes. Its products include MammaPLUS, a breast cancer risk stratifier and a panel of common genetic variants that stratifies individual genetic and background/clinical risk for those at moderately elevated risk for non-familial breast cancer, as well as impacts the risk for developing invasive breast cancer; and Genotype Browser Website that provides a way to access and view the results of a study of genetic variation in various diverse human populations. Perlegen Sciences, Inc. was founded in 2000 and is based in Mountain View, California.